Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation +/- Taxotere (Docetaxel) for Non-metastatic Prostate Cancer Patients With a Rising PSA
Summary
In patients with prostate cancer (PC) who have only biochemically relapsed disease after curative treatment (or some locally advanced PC patients), hormonal therapy remains a de facto standard of care treatment. Adding docetaxel-based chemotherapy to a standard-of-care hormonal therapy has an increased potential to treat prostate cancer cell clones resistant to androgen withdrawal and to possibly shorten the duration of therapy needed to control the disease.
This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) a consensus among investigators on endpoints for studies of patients with a rising PSA, 2) the ability to identify subjects at high risk for developing radiographic metastases, 3) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, and 4) the availability of chemotherapy such as docetaxel that can improve survival in subjects with advanced disease.
It is our hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment.
This trial will determine whether any benefit is gained by adding chemotherapy to hormonal therapy alone in the population of subjects with a rising PSA. Two therapeutic approaches will be compared in this two-arm randomized clinical trial. The control Arm A provides antiandrogen (bicalutamide 150 mg x 1) alone. The experimental Arm B involves treatment with docetaxel for 8-10 cycles and antiandrogen (bicalutamide 150 mg x 1) treatment. For the schematic representation of study design please see Section 7.3.1.
Subjects with a rising PSA following definitive local curative therapy will be eligible, if their PSA doubling time is < 12 months. Also PC patients planned for anti-.androgen therapy are eligible, with the same criteria. Subjects with radiographic metastases will be excluded. The primary endpoint of the trial is progression-free survival of subjects that do not experience biochemical failure at 60 months from the start of therapy.
Based on the yearly number of prostate cancer patients who undergo definitive local therapies and the estimated probabilities of relapse, upwards of 400 men (if +15% improvement) in the Scandinavian countries are potential candidates for this approach.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Copenhagen, Dánsko
- Copenhagen University Hospital, Rigshospitalet
-
-
-
-
-
Turku, Finsko, 20521
- Turku University Hospital
-
-
Kuopio Kuopio
-
Kuopio, Kuopio Kuopio, Finsko, 70211
- Kuopio University Hospital
-
-
-
-
-
Rotterdam, Holandsko, 3015 CE
- Erasmus Medical Center Rotterdam
-
-
-
-
-
Göteborg, Švédsko, 41345
- Sahlgrenska University Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Men > 18 and ≤80 years of age.
- WHO/ECOG performance status 0 - 1 (WHO: World Health Organization; ECOG: Eastern Cooperative Oncology Group )
- Histological proven adenocarcinoma of the prostate.
- Patients who are planned to receive antiandrogen (bicalutamide 150 mg x 1) treatment,
After curative treatment
- Prostatectomy: PSA > 10 OR PSA DT < 12 months and PSA > 0.5 (PSA doubling time calculation must start at a minimum value of > 0.5)
- Radiation: PSA > +2.0 above nadir and PSA >10 OR PSA DT < 12 months and PSA > 0.5. (PSA bouncing after radiotherapy should be excluded according to the local traditions, and PSA doubling time calculation must start at a minimum value of > 0.5)
In locally advanced (or local not suitable for curative therapy) prostate cancer patients, PSA < 100 is required before inclusion AND one of the following
- PSA DT < 12 months or
- PSA >20 or
- Gleason score 8-10
- Previous hormonal therapy in conjunction with radiotherapy is allowed, provided that the total duration of therapy does not exceed 12 months and has to be stopped > 12 months ago.
- Testosterone value > 5 nmol/l
- Adequate haematological-, liver- and kidney function. WBC(white blood cell ) 3.5 x 109/L ANC(absolute neutrophil count ) 1.5 x 109/L Platelet Count 150 x 109/L Haemoglobin > 120 g/L Total bilirubin ≤ ULN (upper limit of normal) unless due to Gilbert's disease Creatinine ≤ 1.5 x ULN or creatinine clearance of 60 cc/min or corresponding Iohexol clearance value ASAT(aspartate aminotransferase )/ALAT(alanine aminotransferase) ≤ 1.5 x ULN ALP (Alkaline phosphatase) < 1.5 x ULN
- Negative bone scan performed no more than 3 months prior to randomisation.
- Additional CT or ultrasound of thorax, abdomen and/or pelvis is optional.
- Written informed consent.
Exclusion Criteria:
- Positive bone scan
- Any distant metastasis detected by CT or ultrasound
- Patients with a history of previous malignant disease. Exceptions should be made for basal cell carcinoma (BCC) and squamous cell carcinoma of the skin. Exceptions should also be made for curatively treated malignant disease, which has been disease free for the past 5 years.
- Previous chemotherapy or randomised in SPCG 12/AdPro or SPCG 13/AdRad (SPCG: Scandinavian Prostate Cancer Group).
- Systemic corticosteroids within 6 months prior to randomisation.
- Unstable cardiovascular disease, including myocardial infarction, within 6 months prior to randomisation.
- Active untreated infectious disease, including tuberculosis, MRSA (Methicillin-resistant Staphylococcus aureus.
- Active gastric ulcer.
- Known hypersensitivity to Polysorbate 80 (an excipient of docetaxel)
- Other serious illness or medical condition
- Symptomatic peripheral neuropathy ≥ CTCAE grade 2.
- Patients who by altered physical or psychological state not are able to co-operate or participate in the trial.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Antiandrogen
Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
|
|
|
Experimentální: Antiandrogen + docetaxel
Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v.
q 3 weeks x up to 8-10 cycles.
|
Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first. Antiemetic therapy may be used if necessary.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression free survival
Časové okno: From date of randomization until the date of first documented progression or date of death from any cause, which ever came first, assessed up to 60 months
|
Progression free survival defined as the time from randomization to the date of first documentation of:
These patients will be followed for evaluation of survival. - Death Death due to prostate cancer in the absence of previous documentation of disease progression, |
From date of randomization until the date of first documented progression or date of death from any cause, which ever came first, assessed up to 60 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Difference between groups in PSA doubling time (PSADT).
Časové okno: From date of randomization until the date of first documented PSADT, assessed up to 60 months
|
The PSADT can be calculated by the natural log of 2 (0.693) divided by the slope of the relation between the log of PSA and the time of PSA measurement.
|
From date of randomization until the date of first documented PSADT, assessed up to 60 months
|
|
Difference between groups regarding QoL
Časové okno: At date of randomization and yearly, assessed up to 60 months
|
The quality of life (QoL) will be assessed using the FACT-P-T disease-specific subscale.
The scoring will be in accordance with version 4 of the FACT manual.
|
At date of randomization and yearly, assessed up to 60 months
|
|
Difference between groups regarding metastasis free survival
Časové okno: From date of randomization until the date of first documented date of metastases, assessed yearly by bone-scan after first PSA_progression until first sign of metastasis, whichever came first, assessed up to 100 months
|
Metastasis free survival will be assessed yearly by bone-scan after first PSA progression until the date of first documented metastasis on bone scan, date of death from any cause, whichever came first, assessed up to 100 months
|
From date of randomization until the date of first documented date of metastases, assessed yearly by bone-scan after first PSA_progression until first sign of metastasis, whichever came first, assessed up to 100 months
|
|
Difference between groups regarding overall survival
Časové okno: From date of randomization until the date of death from any cause reported yearly by the study sites up to 100 months
|
Survival will be assessed yearly up to 100 months after inclusion
|
From date of randomization until the date of death from any cause reported yearly by the study sites up to 100 months
|
|
Difference between groups regarding cancer specific survival
Časové okno: From date of randomization until date of death from prostate cancer,reported yearly by the study sites up to 100 months
|
Cancer specific survival will be assessed yearly up to 100 months after inclusion
|
From date of randomization until date of death from prostate cancer,reported yearly by the study sites up to 100 months
|
|
Measurement of grade of toxicity of given treatments
Časové okno: At date of randomization, during treatment and follow up questionaries until 60 months
|
Adverse events recording using NCI-CTCAE (v3.0)
|
At date of randomization, during treatment and follow up questionaries until 60 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Andreas Josefsson, PhD, Univeristy of Gothenburg
- Vrchní vyšetřovatel: Ingela Turesson, Prof, Uppsala University
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary
- Urogenitální novotvary
- Novotvary podle místa
- Genitální novotvary, muži
- Onemocnění prostaty
- Novotvary prostaty
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Antineoplastická činidla
- Tubulinové modulátory
- Antimitotické látky
- Modulátory mitózy
- Hormony, hormonální náhražky a antagonisté hormonů
- Antagonisté hormonů
- Docetaxel
- Antagonisté androgenů
Další identifikační čísla studie
- version 1.6
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .